{"id":"W2946889769","doi":"10.1200/jco.2019.37.15_suppl.1040","title":"Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with <i>PIK3CA-</i>mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Fulvestrant; Internal medicine; Letrozole; Breast cancer; Oncology; Cohort; Regimen; Palbociclib; Cancer; Metastatic breast cancer; Estrogen receptor; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001891992,0.0008336873,0.001231152,0.0003582611,0.0002391808,0.0008891743,0.0006089967,0.0006387548,0.004629612],"category_scores_gemma":[0.0008240309,0.0003000343,0.001711759,0.0004113806,0.0004215032,0.000880235,0.0004056818,0.002201119,0.0008394668],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006054297,"about_ca_system_score_gemma":0.0007973615,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004909922,"about_ca_topic_score_gemma":0.001954336,"domain_scores_codex":[0.9993927,0.0003721702,0.00003491336,0.00006079476,0.00005458418,0.00008475735],"domain_scores_gemma":[0.9992518,0.0001996812,0.0001918637,0.00007322717,0.00005189678,0.0002314872],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7472209,0.02613607,0.02190567,0.001207091,0.002771163,0.0002245041,0.0002860017,0.002086466,0.0294572,0.0004643539,0.005551634,0.162689],"study_design_scores_gemma":[0.3480755,0.5883142,0.04066494,0.0001462268,0.001678801,0.0008530513,0.0001229972,0.001190425,0.007782375,0.0005250947,0.01060466,0.00004183692],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9862634,0.004816885,0.0006851242,0.0003612648,0.00006932858,0.001152256,0.002591179,0.0000814767,0.003979053],"genre_scores_gemma":[0.9851009,0.002585806,0.001347147,0.0007647095,0.0001106699,0.001117066,0.006615789,0.0000441073,0.002313849],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004629612,"threshold_uncertainty_score":0.01548761,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04594670903478027,"score_gpt":0.4199377363683728,"score_spread":0.3739910273335925,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}